- Home
- ACM vs GMAB Comparison
ACM vs GMAB Comparison
Compare ACM & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACM
- GMAB
- Stock Information
- Founded
- ACM 1980
- GMAB 1999
- Country
- ACM United States
- GMAB Denmark
- Employees
- ACM N/A
- GMAB N/A
- Industry
- ACM Military/Government/Technical
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ACM Consumer Discretionary
- GMAB Health Care
- Exchange
- ACM Nasdaq
- GMAB Nasdaq
- Market Cap
- ACM 17.6B
- GMAB 17.4B
- IPO Year
- ACM 2007
- GMAB N/A
- Fundamental
- Price
- ACM $126.76
- GMAB $30.29
- Analyst Decision
- ACM Strong Buy
- GMAB Strong Buy
- Analyst Count
- ACM 10
- GMAB 6
- Target Price
- ACM $135.10
- GMAB $40.40
- AVG Volume (30 Days)
- ACM 819.9K
- GMAB 2.2M
- Earning Date
- ACM 11-18-2025
- GMAB 11-06-2025
- Dividend Yield
- ACM 0.82%
- GMAB N/A
- EPS Growth
- ACM 42.91
- GMAB 132.41
- EPS
- ACM 4.22
- GMAB 25.10
- Revenue
- ACM $16,139,622,000.00
- GMAB $3,845,670,022.00
- Revenue This Year
- ACM $2.09
- GMAB $24.92
- Revenue Next Year
- ACM $5.05
- GMAB $15.97
- P/E Ratio
- ACM $30.15
- GMAB $1.21
- Revenue Growth
- ACM 0.21
- GMAB 29.57
- 52 Week Low
- ACM $85.00
- GMAB $17.24
- 52 Week High
- ACM $135.52
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- ACM 37.36
- GMAB 55.91
- Support Level
- ACM $131.39
- GMAB $30.08
- Resistance Level
- ACM $134.36
- GMAB $30.89
- Average True Range (ATR)
- ACM 3.02
- GMAB 0.70
- MACD
- ACM -0.45
- GMAB 0.13
- Stochastic Oscillator
- ACM 26.56
- GMAB 80.43
About ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $16.1 billion in sales in fiscal 2024.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.